JP2016537410A5 - - Google Patents

Download PDF

Info

Publication number
JP2016537410A5
JP2016537410A5 JP2016551080A JP2016551080A JP2016537410A5 JP 2016537410 A5 JP2016537410 A5 JP 2016537410A5 JP 2016551080 A JP2016551080 A JP 2016551080A JP 2016551080 A JP2016551080 A JP 2016551080A JP 2016537410 A5 JP2016537410 A5 JP 2016537410A5
Authority
JP
Japan
Prior art keywords
composition according
composition
oligosaccharide
gos
management
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016551080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537410A (ja
JP6890972B2 (ja
Filing date
Publication date
Priority claimed from GBGB1319539.1A external-priority patent/GB201319539D0/en
Application filed filed Critical
Publication of JP2016537410A publication Critical patent/JP2016537410A/ja
Publication of JP2016537410A5 publication Critical patent/JP2016537410A5/ja
Application granted granted Critical
Publication of JP6890972B2 publication Critical patent/JP6890972B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016551080A 2013-11-05 2014-11-05 組成物およびスクリーニング方法 Active JP6890972B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1319539.1A GB201319539D0 (en) 2013-11-05 2013-11-05 Composition & methods of screening
GB1319539.1 2013-11-05
PCT/GB2014/053303 WO2015067949A1 (en) 2013-11-05 2014-11-05 Composition & methods of screening

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019109634A Division JP2019206528A (ja) 2013-11-05 2019-06-12 組成物およびスクリーニング方法

Publications (3)

Publication Number Publication Date
JP2016537410A JP2016537410A (ja) 2016-12-01
JP2016537410A5 true JP2016537410A5 (enExample) 2018-06-14
JP6890972B2 JP6890972B2 (ja) 2021-06-18

Family

ID=49767702

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016551080A Active JP6890972B2 (ja) 2013-11-05 2014-11-05 組成物およびスクリーニング方法
JP2019109634A Pending JP2019206528A (ja) 2013-11-05 2019-06-12 組成物およびスクリーニング方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019109634A Pending JP2019206528A (ja) 2013-11-05 2019-06-12 組成物およびスクリーニング方法

Country Status (7)

Country Link
US (2) US9913857B2 (enExample)
EP (2) EP3892116B1 (enExample)
JP (2) JP6890972B2 (enExample)
AU (2) AU2014345344B2 (enExample)
CA (2) CA2929815C (enExample)
GB (2) GB201319539D0 (enExample)
WO (1) WO2015067949A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
AU2015341571A1 (en) * 2013-11-05 2017-05-18 Optibiotix Limited Prebiotic composition and its method of production
GB201319539D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319531D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
GB201509021D0 (en) * 2015-05-27 2015-07-08 Optibiotix Ltd Methods of screening
GB201509023D0 (en) * 2015-05-27 2015-07-08 Optibiotix Ltd Compositions and methods of production thereof
WO2018023003A1 (en) * 2016-07-29 2018-02-01 Isothrive Llc Optimized individualized prebiotic compositions
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
JP7811843B2 (ja) 2018-07-19 2026-02-06 ペンデュラム セラピューティクス, インコーポレイテッド 微生物生着のための方法および組成物
EP4056052A1 (en) * 2021-03-12 2022-09-14 Biogaia AB Gos pre-conditioning l. reuteri and gos in final formulation
EP4056053A1 (en) * 2021-03-12 2022-09-14 Biogaia AB Pre-conditioning of l. reuteri
CN119451688A (zh) * 2022-07-12 2025-02-14 诺维信公司 用于为乳糖诱导的腹部不适提供缓解的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856259B1 (en) 1996-12-23 1998-08-12 SITIA-YOMO S.p.A. Composition for feed use comprising lyophilized live lactic bacteria
GB0303716D0 (en) * 2003-02-18 2003-03-19 Mars Uk Ltd Food product and process
BRPI0712844A2 (pt) 2006-06-13 2012-07-31 Nestec Sa prevenÇço e tratamento da otite mÉdia com cepas bacterianas nço patogÊnicas.
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
EP2438821B1 (en) 2008-11-03 2020-01-15 Société des Produits Nestlé S.A. A nutritional composition comprising probiotics and improving sleep patterns
EP2216036A1 (en) 2009-02-10 2010-08-11 Nestec S.A. Lactobacillus rhamnosus NCC4007, a probiotic mixture and weight control
WO2010124387A1 (en) * 2009-05-01 2010-11-04 Micropharma Limited Bacterial compositions for prophylaxis and treatment of degenerative disease
US20110117629A1 (en) * 2009-11-19 2011-05-19 Family Medicine Interantional Co., Ltd. Lactobacillus plantarum bb9 capable of adhering to gastrointestinal tract and cholesterol removal
CN102985105B (zh) 2010-01-19 2016-03-09 雅培制药有限公司 包含合生元的营养配方
US20120263696A1 (en) 2011-04-14 2012-10-18 Stefan Roos Indirect Substrates for Microorganisms Metabolizing 1,2-Propanediol
GB201319539D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening

Similar Documents

Publication Publication Date Title
Gulliver et al. the future of microbiome‐based therapeutics
Wang et al. Characteristics of probiotic preparations and their applications
Indira et al. Bioactive molecules of probiotic bacteria and their mechanism of action: a review
Le Doare et al. Mother’s milk: a purposeful contribution to the development of the infant microbiota and immunity
NZ601141A (en) Nutritional formulas containing synbiotics
NZ612386A (en) Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
JP2012520325A5 (enExample)
MY187609A (en) Human milk oligosaccharides to ameliorate symptoms of stress
JP2015523321A5 (enExample)
WO2012024638A3 (en) Compositions and methods for treating obesity by characterizing and restoring mammalian bacterial microbiota
PH12016501953A1 (en) Pediatric nutritional composition with human milk oligosaccharides, prebiotics and probiotics
WO2010146568A3 (en) Bifidobacteria for treating diabetes and related conditions
WO2014006261A3 (es) Micropartículas para encapsulación de probióticos, su obtención y usos
JP2016529309A5 (enExample)
JP2017537156A5 (enExample)
FI3223838T3 (fi) Kultakiivin koostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi
MY158816A (en) Probiotics for reduction of risk of obesity
JP2013139462A5 (enExample)
MX2009009442A (es) Probioticos para mejorar la microbiota intestinal.
WO2009112361A3 (en) Synbiotic mixture
RU2018139655A (ru) Бифидобактерии для увеличения безжировой массы тела
Kamath et al. Translational strategies for oral delivery of faecal microbiota transplantation
Van Niel Probiotics: not just for treatment anymore
RU2018139656A (ru) Бифидобактерии для снижения потребления пищи, энергии и/или жиров
JP2015533484A5 (enExample)